원료의약품
Formoterol Fumarate (포르모테롤푸마르산염)
KDMF APIs
Formoterol Fumarate
품목명 (한글) | 포르모테롤푸마르산염 |
|---|---|
분류 | 호흡기관 |
CAS No. | 43229-80-7 |
KDMF 등록번호 | 20111202-187-I-22-11 |
제조원 | Mylan Laboratories Limited (Unit-11) |
규격 | EP |
품목 정보
IUPAC Name | N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide |
|---|---|
Synonyms | 2'-hydroxy-5'-(1-hydroxy-2-((p-methoxy-α-methylphenethyl)amino)ethyl)formanilide, Formoterol |
Description | Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as salbutamol, combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product and in several formulations in combination with both inhaled corticosteroids and long-acting muscarinic antagonists. |
Certificate of Analysis | If you need more information, please contact us. |
규격서·시험성적서 등 추가 자료가 필요하시면 문의 시 함께 요청해 주세요. 담당자가 확인 후 회신드립니다. (02-579-1056 · ace@acebiopharm.com)